KRTL International Corp and KRTL Biotech Inc. are both subsidiaries of KRTL Holding Group, Inc. KRTL entered into a Memorandum of Understanding for the development of industry-differentiated commercial CBD and other cannabinoid based products with Yuhan Care, a subsidiary of Yuhan Corporation.
We are honored to have Yuhan Care engage with us at KRTL, because they are natural health care professionals inherited innovative research competence from Yuhan Corporation, a 100-year-old company with a pristine reputation in Korea and around the world. Their commitment to quality and transparency is something we strive for at KRTL and a standard that can be emulated by any in the pharmaceutical industry. This agreement allows KRTL to take an incredible step towards our commercial efforts in Korea as the country progresses towards legalization based on the work in the Hemp Free Zone and allows a trusted and significant bridge for CBD products coming into the US from Korea, said Kai Kim, CEO of KRTL International Corporation.
Under this memomorandum of understanding, KRTL will develop joint cannabinoid-based products with Yuhan targeted at the US and Korean commercial markets, develop, distribution channels and partners, and collaborate on various R&D projects within the Korea Hemp Free Zone and throughout the US. This agreement outlines the exclusive use of KRTL's CBD manufacturing partners, which boast cGMP compliance, FDA approval and certified ISO IEC 17025 facilities based in the US, for the sole sourcing of cannabinoid-based products that emerge from this agreement.
Get your daily dose of cannabis news on Benzinga Cannabis.